ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Fluticasone

Also written as “Fluticasone Propionate”, “Fluticasone propionate” and “Fluticasone Propionate/Formoterol Fumarate”.

Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive · Rhinitis, Allergic, Seasonal · Rhinitis, Allergic · Rhinitis, Allergic, Perennial, led by 24 companies.

Drug pageFluticasone: every studyMany companies study it; this page follows only the 150 they lead. All 340 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Feb 1, 2005150 company-led studies, 5 open or runningNext primary completion: Dec 2026 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKlineits history only580 open or runningphase 4since Feb 1, 2005Feb 1, 2005none ahead
Respirent Pharmaceuticalsits history only182 open or runningphase 3since Sep 17, 2018Sep 17, 2018none ahead
Teva Pharmaceutical Industriesits history only140 open or runningphase 4since Dec 11, 2020Nov 22, 2011none ahead
Viatrisits history only130 open or runningphase 4since Dec 16, 2016Nov 21, 2006none ahead
Optinose US101 open or runningphase 3since Jun 13, 2012Jun 13, 2012Mar 31, 2028phase 3 · NCT06850805
Mundipharmaits history only60 open or runningphase 4since Jun 15, 2015Oct 14, 2009none ahead
SkyePharmaits history only50 open or runningphase 3since Oct 27, 2006Oct 27, 2006none ahead
Eurofarma Laboratoriosits history only31 open or runningphase 3since Sep 14, 2010Sep 14, 2010Aug 2028phase 3 · NCT06234345
Merckits history only30 open or runningphase 2since Oct 5, 2006Oct 5, 2006none ahead
Hikma Pharmaceuticalsits history only20 open or runningno phasesince Jan 5, 2016Jan 5, 2016none ahead

Also a collaborator on its studies: Paratek Pharmaceuticals, Becro, Prolytic, Dynamic Solutions, Parexel, Vectura and PPD DEVELOPMENT, LP.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Optinose US only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 13, 2012First studies: 4 phase 3 studiesFirst studyNCT01624662, NCT01622569, NCT01623323 and 1 more
  2. Oct 7, 2014Phase 1 study in Mild to Moderate AsthmaNCT02266927 · 28 enrolled · Ireland
  3. Jun 11, 2018Phase 3 study in Nasal PolypsNCT03591068 · 11 enrolled · United States
  4. Oct 23, 2018Phase 3 study in Bilateral Nasal PolyposisNCT03747458 · 40 enrolled · United States, Argentina
  5. Dec 18, 2018Phase 3 study in Chronic RhinosinusitisNCT03781804 · 332 enrolled · United States, Bulgaria, Canada and more
  6. May 20, 2019Phase 3 study in Chronic RhinosinusitisNCT03960580 · 223 enrolled · United States, Australia, Bulgaria and more
  7. Feb 14, 2025Phase 3 study in Chronic Rhinosinusitis Without Nasal PolypsNCT06850805 · 84 planned · United States

Ahead

  1. Mar 31, 2028Primary completion: phase 3 study in Chronic Rhinosinusitis Without Nasal PolypsNCT06850805

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 10 Optinose US leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06850805Chronic Rhinosinusitis Without Nasal Polyps · United States3RecruitingMar 31, 202884
NCT03960580Chronic Rhinosinusitis · United States, Australia, Bulgaria and more3CompletedMay 4, 2022223
NCT03781804Chronic Rhinosinusitis · United States, Bulgaria, Canada and more3CompletedJan 19, 2022332
NCT03747458Bilateral Nasal Polyposis · United States, Argentina3CompletedMar 31, 202640
NCT03591068Nasal Polyps · United States3CompletedFeb 22, 201911
NCT02266927Mild to Moderate Asthma · Ireland1CompletedMar 201528
NCT01623323Chronic Sinusitis With or Without Nasal Polyps · United States3CompletedMar 2015705
NCT01623310Nasal Polyps · United States3CompletedAug 2015223
NCT01624662Bilateral Nasal Polyposis · United States3CompletedMay 11, 2015323
NCT01622569Bilateral Nasal Polyposis · United States, Canada3CompletedAug 6, 2015323

How it is read

Names in the registry

  • “Fluticasone Propionate”, 17 entries
  • “Fluticasone propionate”, 13 entries
  • “Fluticasone Propionate/Formoterol Fumarate”, 9 entries
  • “fluticasone propionate”, 7 entries
  • “fluticasone propionate/salmeterol”, 7 entries

Codes read as this program: NCX4251, FP100.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.